Should I buy, hold, or sell ITGR stock right now?

Integer Holdings Corporation (ITGR) currently earns a Roarable Rating of C+ (Hold — HOLD) with 67/100 RQD Confidence. Solid 27.0% gross margin (6% return on capital), mixed timing at 42x P/E—hold if owned, no rush to chase.

What is ITGR's 12-month price target and RQD AI Jury consensus?

ITGR's 12-month base price target is $131.68 (range $102.71 to $155.38), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / ITGR

LIVN (66) AXGN (53) TMDX (61) CNMD (62) ⌘ Pro Terminal →

Integer Holdings Corporation (ITGR) — RQD Stock Rating Cockpit

$126.55 -0.03% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $126.30

Integer Holdings Corporation (ITGR) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $4.30B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ITGR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ITGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Integer Holdings Corporation (NYSE: ITGR) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $126.55 (-0.03% 1D, market cap $4.30B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, ITGR ranks #105 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ITGR compare to LIVN and AXGN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), ITGR carries a Roarable C+ (67/100 RQD), trailing P/E of 41.8x, gross margin of 27.0%, and ROIC of 6.0%. By comparison, LIVN (LivaNova PLC) holds a C+ grade (66/100 RQD, P/E N/A, ROIC 17.3%, cap $4.35B) and AXGN (Axogen Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -2.6%, cap $2.95B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ITGR?

▼

Per ITGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001114483), Integer Holdings Corporation generated $1.85B in revenue (+8.0% YoY), $102.8M in net income, and $105.1M in free cash flow against $3.41B in total assets and $1.19B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $126.30 (-0.20%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 5.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ITGR)Realized 20D OHLCV Swing Band: ±1.8%

Deterministic 5-Pillar Attribution (67/100 Composite)

🔍 WHY ITGR SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (24% of score)

20D Institutional Volume Accumulation (±1.8% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 5.7% FCF Margin ($105.1M FCF) & 27% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$126.61+0.1% Next Q

Q2 (-2Q)

Grade B$126.70-0.1% Next Q

Q3 (-1Q)

Grade B$126.55+0% Next Q

Current

Grade C+$126.55+1.6% Hist 90D α

Trajectory: B+ (75) → C+ (67)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ITGR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, ITGR faces multiple-compression risk if 41.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 42x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 24.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($126.28) or 200D SMA ($101.43) invalidates the momentum regime and cuts Target Base ($131.68) toward Bear Floor ($102.71).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ITGR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ITGR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 67%NO 33%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

61.430 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.91>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE99% OF RANGE

L: $64$126.55H: $127

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (27.0% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on ITGR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (70)

6.0% ROIC with 27.0% gross margin and 2.44% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 2.91 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (67)

27/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like ITGR

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Priced at 42x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ITGR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ITGR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.74%⚡ TESTING RESISTANCE

2026-11-03O $126.5H $126.6L $126.5C $126.6VOL 571.7K

RES: $126.8SUP: $126.6SMA50: $126.3SMA200: $101.4

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ITGR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ITGR Butterfly Map → + Track ITGR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

31.6%/yr Implied 5Y Growth

vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ITGR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ITGR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ITGR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ITGR)

Health Care Rank #105 of 1015 ⚔️ LIVN vs ITGR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ITGR vs. LIVN, AXGN, TMDX, CNMD)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Integer Holdings Corporation (ITGR) ranks #105 by composite RQD confidence (67/100, grade C+) and #171 by equity capitalization ($4.30B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. ITGR currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ITGR ACTIVE Integer Holdings Corporation	C+	67/100	41.8x	27.0%	6.0%	-0.03%	$4.30B	Benchmark Subject
LIVN LivaNova PLC	C+	66/100	—	67.7%	17.3%	+1.57%	$4.35B	/livn-vs-itgr →
AXGN Axogen Inc.	D+	53/100	—	74.3%	-2.6%	+0.97%	$2.95B	/axgn-vs-itgr →
TMDX TransMedics Group Inc.	C-	61/100	12.2x	59.9%	18.1%	+1.03%	$2.29B	/tmdx-vs-itgr →
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	+5.19%	$1.32B	/cnmd-vs-itgr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001114483 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Integer Holdings Corporation (ITGR) reported GAAP revenue of $1.85B (+8.0% vs. FY2024 revenue of $1.72B , and +19.2% cumulative change since FY2023) , GAAP net income of $102.8M, operating cash flow of $196.1M, and free cash flow of $105.1M (+5.3% YoY). On the balance sheet, ITGR closed FY2025 with $3.41B in total assets against $1.19B in total debt (Altman Z-Score: 2.91, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.85B	$102.8M	$196.1M	$105.1M	$3.41B	$1.19B
FY2024 (FY)	2024-12-31	$1.72B	$119.9M	$205.2M	$99.8M	$3.08B	$980.2M
FY2023 (FY)	2023-12-31	$1.56B	$90.7M	$180.2M	$110.2M	$2.37B	$553.5M

3. ITGR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ITGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ITGR compare to LIVN and AXGN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ITGR?

Where is ITGR trading relative to its 50-day, 200-day, and 52-week technical levels?

ITGR last traded at $126.55 (-0.03% on volume of 509,244 shares), positioning the stock +0.21% above its 50-day simple moving average ($126.28) and +24.77% above its 200-day simple moving average ($101.43). Across its 52-week range of $63.75 to $126.83, ITGR sits at the 99.6% percentile with a 14-day RSI of 61.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($124.27 to $128.83).

Direct Sub-Reports: ITGR RQD Cockpit ITGR 12M Forecast ITGR Earnings & Move ITGR Dividends & DRIP ITGR Insiders & 13F ITGR Whale Options ITGR Profit Sankey ITGR News & Why

ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ SEC XBRL & RQD VERIFIED

ITGR — Integer Holdings Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Integer Holdings Corporation (ITGR) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $126.55 (-0.03% 1D, market capitalization $4.30B).

Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 6.0%, gross margin of 27.0%, operating margin of 11.9%, and free cash flow yield of 2.44%.
Whale 13F & Options Flow (16/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (13/20) + Forensic Balance Sheet (13/20): Incorporates a 1.02x equity beta, Altman Z-Score of 2.91, Piotroski F-Score of 7/9, and Debt/Equity of 0.68x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Integer Holdings Corporation operates in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry,. It trades on the NYSE under the ticker ITGR.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Integer Holdings Corporation (ITGR) reported $1.85B in annual revenue (up from $1.72B in FY2024, +8.0% YoY) and $102.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.56B revenue, $90.7M net income) through FY2025, ITGR scaled operating cash flow to $196.1M and free cash flow to $105.1M, backed by $3.41B in total assets against $1.19B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C+ • RQD 67/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 2.44% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $63.75 – $126.83 52-week range.
🐻 Primary Bear Case & Valuation Risk: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 41.8x trailing P/E and 18.3x EV/EBITDA against 11.9% operating margins and a 1.02x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), ITGR carries a macro regime beta of 1.02 and gross margin of 27.0%.

Key Question #1: Can ITGR sustain or expand its 11.9% operating margin and 6.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.85B and free cash flow of $105.1M, how will capital allocation balance growth reinvestment against $1.19B in total debt?
Key Question #3: How sensitive is ITGR's 38.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.02x)?

ITGR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Integer Holdings Corporation (ITGR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ITGR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 3d ago

Integer Holdings (ITGR) Q3 Results Expose Earnings Slide Behind Rich P/E

Integer Holdings barely moved in regular trading, with the stock edging up 0.06% to close at $126.59, yet the fresh Q3 2026 numbers tell a much tighter story beneath that calm surface. Net income from ongoing operations

Read Full Source ↗

🔴 RISK WATCH Yahoo • 4d ago

Integer Holdings (NYSE:ITGR) misses Q3 2026 revenue estimates

Medical technology company Integer Holdings (NYSE:ITGR) fell short of the market’s revenue expectations in Q3 2026, with revenue falling 3.9% year on year to $449.7 million. Its non-GAAP profit of $1.34 per share was 20.

Read Full Source ↗

🟡 MARKET WIRE Fintel • 4d ago

Integer Holdings Corporation Reports Third Quarter 2026 Results

Read Full Source ↗

🔴 RISK WATCH Yahoo • 5d ago

Integer (ITGR) Q3 Earnings and Revenues Miss Estimates

Integer (ITGR) delivered earnings and revenue surprises of -18.79% and -1.67%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 5d ago

Integer: Q3 Earnings Snapshot

PLANO, Texas (AP) — PLANO, Texas (AP) — Integer Holdings Corp. (ITGR) on Thursday reported third-quarter earnings of $15 million.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 5d ago

Integer Holdings Q3 Adj. EPS $1.34 Misses $1.69 Estimate, Sales $449.661M Miss $457.154M Estimate

Integer Holdings (NYSE:ITGR) reported quarterly earnings of $1.34 per share which missed the analyst consensus estimate of $1.69 by 20.71 percent. This is a 25.14 percent decrease over earnings of $1.79 per share from

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Can Integer Holdings (ITGR) Trade Below Fair Value Near Its Deal Price?

Integer Holdings has delivered a sharp rerating over the past year, and its share price now aligns with an agreed buyout proposal from KKR that values the business at several billion dollars. With the stock trading near

Read Full Source ↗

🟡 MARKET WIRE Fintel • 12d ago

Integer Holdings Corporation Stockholders Approve Merger Agreement with 26,065,335 Votes in Favor

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ITGR Bull vs. Bear Conversation Board — What's Your Call at $126.55?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ITGR 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $149.38 (+18.0%)

📌 Pinned Debate

Institutional positioning scores 16 of 20 in the RQD and the Piotroski F-Score is 7 of 9, indicating strong institutional interest and

Here is why I am bullish on ITGR here at $126.59: Institutional positioning scores 16 of 20 in the RQD and the Piotroski F-Score is 7 of 9, indicating strong institutional interest and solid balance sheet signals.. Compare ITGR's 11.9% operating margin and 6.0% ROIC against the rest of Biotechnology: Electromedical & Electrotherapeutic Apparatus. As long as cash conversion holds up, dips toward $120.26 are getting bought.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on 41.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Electromedical & Electrotherapeutic Apparatus. If gross margin (27.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $108.87 (-14.0%)

Spot @ $126.59

Debt rose from $553.5M to $1.19B while cash fell to $17.2M, and a P/E (TTM) of 41.8 sits against a 2.44% FCF yield.

Careful chasing ITGR at $126.59. Debt rose from $553.5M to $1.19B while cash fell to $17.2M, and a P/E (TTM) of 41.8 sits against a 2.44% FCF yield.. Gross margin is 27.0%, but operating margin is 11.9%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $108.87 on multiple compression.